Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Campbell SC, Clark JI, et al. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003;4:385-90
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology – Kidney Cancer version 3.2014. Fort Washington, PA: National Comprehensive Cancer Network, 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf [Last accessed 14 May 2014]
   Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:3312-18
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:2144-50
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 2014;32:760-7
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:286-96
   PubMed Web of Science ®Google Scholar
• Busch J, Seidel C, Kempkensteffen C, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011;60:1163-70
   PubMed Web of Science ®Google Scholar
• Chen C-C, Hess GP, Liu Z, et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2012;10:256-61
   PubMed Web of Science ®Google Scholar
• Feinberg BA, Jolly P, Wang S-T, et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol Northwood Lond Engl 2012;29:786-94
   PubMed Web of Science ®Google Scholar
• Park K, Lee J-L, Park I, et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol Northwood Lond Engl 2012;29:3291-7
   PubMed Web of Science ®Google Scholar
• Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010;76:430-4
   PubMed Web of Science ®Google Scholar
• Giuliani J, Drudi F. Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence? Cancer Biother Radiopharm 2012;27:513-18
   PubMed Web of Science ®Google Scholar
• Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev Anticancer Ther 2011;11:639-49
   PubMed Web of Science ®Google Scholar
• Porta C, Sabbatini R, Procopio G, et al. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther 2012;12:1571-7
   PubMed Web of Science ®Google Scholar
• Wong MK, Yang H, Signorovitch JE, et al. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin 2014;30:537-45
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Casciano R, Malangone E, et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 2011;12:1491-7
   PubMed Web of Science ®Google Scholar
• Heng D. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2012;30(Suppl 5):abstr 387
   Web of Science ®Google Scholar
• Yang H, Wong MKK, Signorovitch JE, et al. Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: a retrospective U.S. chart review. J Clin Oncol 2012;30:(suppl): abstr 4612
   Web of Science ®Google Scholar
• Ryan CJ, Green MR, Britton SL, et al. Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 2014;32(suppl 4): abstr 492
   Web of Science ®Google Scholar
• Signorovitch JE, Vogelzang NJ, Pal SK, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin 2014, in press
   Web of Science ®Google Scholar